Two more SGLT2 inhibitors recommended in Japan
This article was originally published in Scrip
Japan has recommended the approval of another two sodium glucose co-transporter 2 (SGLT2) inhibitor drugs for type 2 diabetes, Taisho's luseogliflozin and Sanofi/Kowa's tofogliflozin (licensed from Chugai), setting the stage for a major marketing battle later this year.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.